Axsome Therapeutics (AXSM)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$1.66 (+1.67%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Axsome Therapeutics (AXSM)
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.

Key Insights

Critical company metrics and information

  • Share Price

    $102.05

  • Market Cap

    $4.95 Billion

  • Total Outstanding Shares

    48.46 Million Shares

  • Total Employees

    589

  • Dividend

    No dividend

  • IPO Date

    November 19, 2015

  • SIC Description

    Pharmaceutical Preparations

  • Homepage

    https://www.axsome.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Investing Activities$247000.00
Net Cash Flow From Operating Activities$-132.57 Million
Net Cash Flow, Continuing$-89.22 Million
Net Cash Flow From Financing Activities$43.59 Million
Net Cash Flow From Operating Activities, Continuing$-132.57 Million
Net Cash Flow$-89.22 Million
Net Cash Flow From Investing Activities, Continuing$247000.00
Net Cash Flow From Financing Activities, Continuing$43.59 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Research and Development$162.87 Million
Diluted Average Shares$143.75 Million
Operating Income/Loss$-306.22 Million
Preferred Stock Dividends And Other Adjustments$0.00
Diluted Earnings Per Share$6.58
Basic Earnings Per Share$6.58
Revenues$338.46 Million
Income Tax Expense/Benefit$325000.00
Other Operating Expenses$96.91 Million
Basic Average Shares$143.75 Million
Net Income/Loss Attributable To Parent$-310.95 Million
Net Income/Loss$-310.95 Million
Selling, General, and Administrative Expenses$384.90 Million
Costs And Expenses$644.68 Million
Income/Loss From Continuing Operations Before Tax$-311.28 Million
Income/Loss From Continuing Operations After Tax$-310.95 Million
Benefits Costs and Expenses$649.74 Million
Net Income/Loss Available To Common Stockholders, Basic$-310.95 Million
Operating Expenses$644.68 Million

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Equity Attributable To Parent$92.90 Million
Other Current Liabilities$112.57 Million
Fixed Assets$683000.00
Assets$561.46 Million
Current Liabilities$196.19 Million
Wages$19.37 Million
Equity Attributable To Noncontrolling Interest$0.00
Intangible Assets$48.50 Million
Inventory$14.27 Million
Noncurrent Assets$82.34 Million
Liabilities And Equity$561.46 Million
Accounts Payable$64.25 Million
Noncurrent Liabilities$272.37 Million
Current Assets$479.11 Million
Liabilities$468.56 Million
Other Non-current Assets$33.16 Million
Equity$92.90 Million
Other Current Assets$464.85 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
Earnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

ⓒ 2024 Financhle. All Rights Reserved.